Zhittya gets regulatory approval in Mexico for trial of drug in PD patients
Zhittya Genesis Medicine has secured regulatory approval from Mexico's governing body COFEPRIS to test its drug in people with Parkinson's disease (PD).
Synthetic peptide drugs less likely to be approved than recombinant peptide drugs
GlobalData’s Likelihood of Approval (LoA) tool in the Drugs database considers the case for pipeline recombinant peptide drugs.
Givlaari™ (givosiran) for the Treatment of Acute Hepatic Porphyria
Givlaari™ (givosiran) is the first aminolevulinic acid synthase 1 (ALAS1)-targeting RNAi drug indicated for the treatment of acute hepatic porphyria (AHP) in adults.
Abeona to initiate Phase III trial of EB-101 to treat RDEB
Abeona Therapeutics is ready to initiate its pivotal Phase III clinical trial, VIITAL, to evaluate EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
VUMERITY (diroximel fumarate) for the Treatment of Multiple Sclerosis
VUMERITY™ (diroximel fumarate), previously known as ALKS 8700, is a novel oral formulation indicated for the treatment of relapsing forms of multiple sclerosis (MS).
Secuado (asenapine) for the Treatment of Schizophrenia
Secuado® (asenapine) is an atypical anti-psychotic drug approved for the treatment of schizophrenia in adult patients. It is the first drug approved as transdermal patch formulation for schizophrenia treatment in the US.